Cullinan Oncology and MAB Discovery Announce Collaboration to Develop Novel Antibody-Based Therapeutics Cullinan Oncology and MAB Discovery Announce Collaboration to Develop Novel Antibody-Based Therapeutics Kristen Laguerre2018-02-20T08:05:34+00:00February 20, 2018| Read More
Cullinan Oncology Adds Industry Leaders to Board, Bringing Significant Business & Healthcare Acumen Cullinan Oncology Adds Industry Leaders to Board, Bringing Significant Business & Healthcare Acumen Kristen Laguerre2017-11-29T10:12:21+00:00November 29, 2017| Read More
With $150m in its pocket, new cancer startup will turn to CROs to ‘execute faster’ Kristen Laguerre2017-11-03T13:03:18+00:00October 5, 2017| Read More
Cullinan Secures $150M to Build Oncology Portfolio from ‘Diamonds in the Rough’ Kristen Laguerre2017-11-03T13:03:35+00:00October 4, 2017| Read More
Cullinan Oncology Emerges with $150 Million and a Roster of All-Star Biotech Scientists Kristen Laguerre2017-11-03T13:03:50+00:00October 3, 2017| Read More
Cambridge biotech startup raises $150 million to develop cancer drugs Kristen Laguerre2017-11-03T13:04:16+00:00October 3, 2017| Read More
Top scientists and BD execs craft Cullinan, a $150 million R&D portfolio shop focused on cancer Kristen Laguerre2017-11-03T13:04:30+00:00October 3, 2017| Read More
Cullinan Oncology Emerges with $150M to Build Cancer Drug Portfolio Kristen Laguerre2017-11-03T13:04:55+00:00October 3, 2017| Read More
Cullinan Bags $150M to Build Broad Slate of Cancer Assets Kristen Laguerre2017-11-03T13:05:15+00:00October 3, 2017| Read More
Ex-Intarcia dealmaker lands $150M for new cancer drug startup Cullinan root2017-11-03T13:05:34+00:00October 3, 2017| Read More
